Table 3.
Annualized rates of change in BPF estimates by disease phenotype adjusted for baseline covariates with 95% CI according to PPMS vs. SPMS. (1 study year is defined as 48 weeks).
| Disease Phenotype |
Estimated rate of BPF change (95% CI) |
Estimated difference in rate of change (95% CI) |
P‐value for difference in rate of change | |
|---|---|---|---|---|
| Ibudilast | Placebo | |||
| −0.00079 | −0.00243 | 0.001646 | <0.01 | |
| PPMS 1 | (−0.00164, 0.000067) | (−0.00326, −0.00161) | (0.000459, 0.002833) | |
|
SPMS 1 |
−0.00112 | −0.00115 | 0.000037 | 0.95 |
| (−0.00204, −0.00019) | (−0.00205, −0.00026) | (−0.00125, 0.001322) | ||
1
Estimated rates of change by disease phenotype from a model adjusted for baseline T2 lesion volume, retinal nerve fiber thickness, longitudinal diffusivity, and age.